About molinger

This author has not yet filled in any details.
So far molinger has created 1 blog entries.

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

October 04, 2019 12:50 PM Eastern Daylight Time CAMBRIDGE, Mass. (BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks of study treatment in CENTAUR, a clinical trial assessing the safety and [...]